Abstract
Nicotine use disorder remains a major public health emergency despite years of trumpeting the consequences of smoking. This is likely due to the complex interplay of genetics and nicotine exposure across the lifespan of these individuals. Genetics influence all aspects of life, including complex disorders such as nicotine use disorder. This review first highlights the critical neurocircuitry underlying nicotine dependence and withdrawal, and then describes the cellular signaling mechanisms involved. Finally, current genetic, genomic, and transcriptomic evidence for new drug development of smoking cessation aids is discussed, with a focus on the Neuregulin 3 Signaling Pathway.
| Original language | English |
|---|---|
| Pages (from-to) | 387-404 |
| Number of pages | 18 |
| Journal | Advances in Pharmacology |
| Volume | 99 |
| DOIs | |
| State | Published - Jan 2024 |
Bibliographical note
Publisher Copyright:© 2024
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- CREB
- ErbB4
- Neuregulin 3
- Smoking cessation
- Tobacco Use Disorder
ASJC Scopus subject areas
- Pharmacology
Fingerprint
Dive into the research topics of 'Nicotine use disorder and Neuregulin 3: Opportunities for precision medicine'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver